Skip to main content
. 2022 Nov 24;23(23):14687. doi: 10.3390/ijms232314687

Figure 3.

Figure 3

Recurrence-free survival analysis of ovarian cancer patients for EpCAM and CD45 expression in hybrid cells at the baseline and at second follow-up. The expression of this markers showed a worse RFS of 5.26 months vs. 12.2 (p = 0.005) in relation to those who did not.